Onyx's higher marketing expenses for Kyprolis seen as money well spent
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals won't offer sales projections for its multiple myeloma drug Kyprolis (carfilzomib), which won accelerated US FDA approval on 20 July for patients who failed treatment with at least two prior therapies (scripintelligence.com, 23 July 2012), but stock analysts offered their own opinions on the drug's value after the firm announced its second quarter 2012 financial results.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.